Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
Chemotherapy given in combination with ligands for the peroxisome proliferator-activated receptor - (PPAR) synergistically inhibits the growth of lung and ovarian cancer cell lines.
化疗药物联合过氧化物酶体增殖物激活受体(PPAR)的配体能够协同抑制肺细胞癌及卵巢癌细胞。
应用推荐